Google
Trusted Resources: Evidence & Education
Scientific literature and patient education texts
Blood exchange transfusion safety for priapism in sickle cell disease: a single institution review
source: The American Society of Pediatric Hematology/Oncology
year: 2016
authors: Maria O. Boucher, Patience Obasaju, Yara A. Park, Rupa Redding-Lallinger
summary/abstract:Background: Males with sickle cell disease (SCD) have a 29-42% lifetime probability of developing priapism. Management of priapism is controversial and not evidence-based. Red cell exchange transfusion has been used to manage sickle related complications but several case reports have described acute neurological events following exchange transfusion for priapism, which limits enthusiasm for routine adoption of this therapy. Presently there are little data characterizing exchange transfusions utility and safety in treating priapism.
Objectives: To determine and compare the incidence of adverse events seen in patients with SCD receiving red cell exchange transfusion for refractory priapism and secondary stroke prophylaxis.
Design/Method: The University of North Carolina’s blood bank database was used to identify patients with SCD who were enrolled on chronic exchange transfusion program for refractory priapism from years 2004- 2015. An age-matched cohort of seven patients enrolled in exchange protocol for secondary stroke prophylaxis was identified.The first exchange procedure for both groups will be used for comparison. Adverse events such as vital sign instability and acute neurologic events were collected. Data collected will be analyzed to determine if there is a difference in adverse events in the priapism group compared to those receiving exchange transfusions for secondary stroke prophylaxis.
Results: We identified seven patients with SCD who were enrolled on a red cell exchange protocol for refractory priapism. We evaluated 6 episodes of exchange transfusions per patient. The mean age was 24; six patients have HbSS and one patient has HbSC. Two episodes of hypotension were recorded in one patient on two separate procedures.This resolved after decreasing the inlet pump flow rate to the patient. No adverse neurologic events were recorded. One patient experienced lip tingling that resolved with calcium carbonate tablets.The comparison data for the patients being transfused for secondary stroke prevention is being collected.
Conclusion: Although exchange transfusion is infrequently used for treating refractory priapism in patients with SCD, the incidence of adverse events appears to be minimal. Analysis is ongoing to compare the safety of red cell exchange transfusion for priapism to stroke.Future controlled trials using blood exchange transfusion for refractory priapism are needed.
read more
+myBinderRelated Content
-
Crizanlizumab 5.0 mg/kg increased the time to first on-treatment sickle cell pain crisis: a subgroup analysis of the...In the 52-week SUSTAIN study, which comp...
-
Differences in Brain Oxygen Supply May Explain Silent Strokes in SCD PatientsBrain oxygen supply is different in diff...
-
Sickle Cell PainSickle Cell Pain is a panoramic, in-dept...
-
Matthew Porteus awarded grant for sickle cell anemia workThe California Institute for Regenerativ...
-
Today’s Faces of Sickle Cell Disease: Courtney Fitzhugh, M.D.Courtney Fitzhugh first became intereste...
-
Novel Sickle Cell Drug Causes Radical Results in End of Life PatientsThis week the FDA approved a novel treat...
-
A Teenager’s Breakthrough Gene Therapy for Sickle Cell DiseaseMeet Helen Obando, a shy 16-year-old who...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Support for this site is provided by
This platform is made possible through a partnership with the Sickle Cell Disease Association of America, Inc. (SCDAA) and its member organizations. SCDAA's mission is to advocate for people affected by sickle cell conditions and empower community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure.